Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GW685698X Aqueous Nasal Spray
GW685698X Aqueous · 5 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GW685698X Aqueous Nasal Spray | DRUG | - |
Inclusion criteria: * Must be outpatients. * Diagnosis of SAR. * Literate in English or native language. Exclusion criteria: * Have a significant concomitant medical condition. * Use corticosteroids or other allergy medications during the study. * Use tobacco products.
GW685698X Aqueous is an investigational small molecule nasal spray being developed by GSK plc for allergic rhinitis. It is studied in both seasonal and perennial allergic rhinitis, which are nasal allergy conditions triggered by seasonal pollens or year-round allergens. It is in Phase 3 clinical development.
GW685698X Aqueous is being studied for the treatment of allergic rhinitis, including seasonal allergic rhinitis and perennial allergic rhinitis. Seasonal allergic rhinitis is triggered by pollens such as grass or tree pollen, while perennial allergic rhinitis is triggered by year-round allergens such as dust mites or pet dander.
GW685698X Aqueous is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical trials evaluating the nasal spray in patients with seasonal and perennial allergic rhinitis.
GW685698X Aqueous is in Phase 3 clinical development. It is an investigational product and has not been approved by the FDA. All three completed trials were Phase 3 studies, and no active trials are currently listed.
GW685698X Aqueous has been evaluated in Phase 3 trials including NCT00363740 in seasonal allergic rhinitis, NCT00197262 and NCT00118729 in seasonal allergic rhinitis, and NCT00116883 in pediatric perennial allergic rhinitis. All four trials are completed, with a combined enrollment of 706 participants.
Yes, GW685698X Aqueous is also known as GW685698X Aqueous Nasal Spray or GW685698X aqueous nasal spray. These names refer to the same investigational nasal spray product developed by GSK plc for allergic rhinitis.